Biocept (FRA:B00) ROCE % : -79.52% (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biocept ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biocept's annualized ROCE % for the quarter that ended in Jun. 2023 was -79.52%.

Biocept ROCE % Historical Data

The historical data trend for Biocept's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept ROCE % Chart

Biocept Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-718.58

-306.92

-72.78

-5.94

-89.89

Biocept Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
ROCE %	Get a 7-Day Free Trial															-83.76	-90.13	-108.14	-128.37	-79.52

Biocept ROCE % Calculation

Biocept's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-30.11	/	( ( (53.469 - 10.419)	+	(29.144 - 5.198) )	/ 2 )
	=	-30.11	/	( (43.05	+	23.946)	/ 2 )
	=	-30.11	/	33.498
	=	-89.89 %

Biocept's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	-13.22	/	( ( (21.475 - 4.102)	+	(20.401 - 4.525) )	/ 2 )
	=	-13.22	/	( ( 17.373	+	15.876 )	/ 2 )
	=	-13.22	/	16.6245
	=	-79.52 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

Biocept (FRA:B00) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biocept ROCE % Related Terms

Thank you for viewing the detailed overview of Biocept's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocept (FRA:B00) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (FRA:B00) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BIOCQ:USA

Address

9955 Mesa Rim Road, San Diego, CA, USA, 92121

Website

https://www.biocept.com

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Biocept (FRA:B00) Headlines

No Headlines